Investigational Drug Information for Ridinilazole
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the drug development status for Ridinilazole?
Ridinilazole is an investigational drug.
There have been 4 clinical trials for Ridinilazole.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 19th 2021.
The most common disease conditions in clinical trials are Clostridium Infections, Infections, and Infection. The leading clinical trial sponsors are Summit Therapeutics, Department of Health and Human Services, and [disabled in preview].
There are four US patents protecting this investigational drug and eighty-one international patents.
Summary for Ridinilazole
| US Patents | 4 |
| International Patents | 81 |
| US Patent Applications | 37 |
| WIPO Patent Applications | 27 |
| Japanese Patent Applications | 6 |
| Clinical Trial Progress | Phase 2 (2021-05-19) |
| Vendors | 23 |
Recent Clinical Trials for Ridinilazole
| Title | Sponsor | Phase |
|---|---|---|
| Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects | Department of Health and Human Services | Phase 3 |
| Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects | Summit Therapeutics | Phase 3 |
| Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection | Summit Therapeutics | Phase 3 |
Clinical Trial Summary for Ridinilazole
Top disease conditions for Ridinilazole
Top clinical trial sponsors for Ridinilazole
US Patents for Ridinilazole
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Ridinilazole | See Plans and Pricing | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | See Plans and Pricing |
| Ridinilazole | See Plans and Pricing | Oral drug dosage forms having desired drug release profiles and uses thereof | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| Ridinilazole | See Plans and Pricing | Compartmented pharmaceutical dosage forms | Triastek, Inc. (Nanjing, CN) | See Plans and Pricing |
| Ridinilazole | See Plans and Pricing | Halogenated salicylanilides for treating clostridium infections | UNION therapeutics A/S (Hellerup, DK) | See Plans and Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Ridinilazole
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Ridinilazole | Australia | AU2017261372 | 2036-05-05 | See Plans and Pricing |
| Ridinilazole | Canada | CA3023278 | 2036-05-05 | See Plans and Pricing |
| Ridinilazole | China | CN107847398 | 2036-05-05 | See Plans and Pricing |
| Ridinilazole | European Patent Office | EP3452003 | 2036-05-05 | See Plans and Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
